Purge system for nitric oxide administration apparatus and method of purging the system

Abstract: A nitric oxide delivery system is disclosed that delivers a pulsed volume of NO containing therapeutic gas to a patient upon each inhalation of the patient. The NO delivery system includes certain functions to provide protection against the inadvertent inclusion of NO 2 in the therapeutic gas administered to the patient. One of the functions is to provide a purge upon start up of the delivery system apparatus that clears the regulator (14) and conduits (18) of any NO 2 that may have formed during the prior idle period of the system. A detector determines the start-up and may automatically carry out the purge cycle or may cause a prompt that is visual or audible (34, 36) to remind the user to carry out the purge cycle manually. As a further function, when the NO apparatus is terminated with respect to a patient, the system can, again, sense the termination or cessation of the therapy and automatically shut off the supply of NO containing gas at the source (12) or provide an audible or visual prompt (34,36) to remind the user to shut off the supply of the NO containing gas manually.

Description: This invention relates to the administration of a therapeutic gas such as nitric oxide (NO) to patients for therapeutic effect. In particular, it relates to a system wherein a controlled, predetermined dose of NO is provided to the patient with each inhalation by the patient and to the use of various functions utilized by that system to control and/or eliminate nitrogen dioxide (NO 2 ) from the system for safety reasons. The function of the administration of NO has been fairly widely published and typical articles appeared in The Lancet, Vol. 340, October 1992 at pages 818-820 entitled "Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn" and "Low-dose Inhalational Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn" and in Anesthesiology, Vol. 78, pgs. 413-416 (1993), entitled "Inhaled NO-the past, the present and the future". The actual administration of NO is generally carried out by its introduction into the patient as a gas and commercially available supplies are provided in cylinders under pressure and may be at pressures of about 2000 psi and consist of a predetermined mixture of NO in a carrier gas such as nitrogen. A pressure regulator is therefore used to reduce the pressure of the supply cylinder to working levels for introduction to a patient. The concentration administered to a patient will vary according to the patient and the need for the therapy but will generally include concentrations at or lower than 150 ppm. There is, of course, a need for that concentration to be precisely metered to the patient since an excess of NO can be harmful to the patient. One current known method and apparatus for the administration of NO to patients is described in U.S. Patent 5,558,083 where a system is provided that can be added to any ventilator and which will meter in the desired concentration of NO into the gas supplied from that ventilator. Various other delivery devices have also been used that respond to the patient attempting to inhale to deliver a pulsed dose of NO to the patient and such pulsing devices have also been shown to have therapeutic effect on the patient, for example, as described in Higenbottam PCT patent application WO 95/10315 and the publication of Channick et al "Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension", Chest/109/ June 1996. In such pulsatile dosing devices, a pulse of NO is administered to the patient as the patient inhales spontaneously. The inhalation pulsing type devices are typically shown and described in Durkan, U.S. Patent 4,462,398. Another such apparatus is described in pending U.S. Patent application entitled "Constant Volume NO Pulse Delivery Device", filed on the same day as the present application and owned by the same assignee. One difficulty with such devices that provide a supplemental therapeutic gas to the patient concerns the formation of NO 2 from NO. NO 2 is a toxic compound and its presence is, therefore, undesirable in any appreciable concentration in the gas administered to the patient. Such toxic effects are present at concentrations of about 5 ppm and therefore even minute quantities of NO 2 cannot be tolerated. In the pulse dose devices that administer NO as a supplemental therapeutic gas to the patient, there is likely to be no monitor to sense the presence of NO 2 and therefore it is important to take preventative measures in the system itself to assure that the formation of NO 2 does not occur, or when it does occur, to remove the NO 2 from the system before the NO containing therapy gas is delivered to the patient. The formation of NO 2 results from the reaction of NO with O 2 and therefore there is ample opportunity in the administration of NO to a patient for NO 2 to be formed. One possibility is when the administration device is connected to the NO therapy gas source, air can be trapped in the cylinder valve and regulator fittings when the connection is made and because the NO in the cylinder is typically only a few hundred parts per million even small volumes of air can provide enough oxygen to cause significant proportions of the NO to react and form NO 2 . Another possibility is that air can be trapped in passages of the regulator and regulator pressure gauge and which are not in the main flow passages. The main passages are cleared of air during use by the flow of NO therapy gas from the cylinder, however, when the device is turned off for any length of time the O 2 in the air can diffuse out of these passages and can react with NO in the regulator and, if the cylinder valve is left open, the O 2 can diffuse into the cylinder and react with the NO in the cylinder. The reaction of NO and O 2 to form NO 2 is a time related reaction, that is, the more time that the NO is in association with the O 2 , the more NO 2 is formed, therefore it is important to provide prevention measures wherever there is any time period where the NO and O 2 can be in contact with each other and provide means for removing the NO 2 from the system. Two of the rather critical periods where sufficient time can elapse and where NO and O 2 may intermix and where the formation of NO 2 may therefore occur are during start-up where NO may have been left in the system in contact with O 2 from the prior use of the delivery system and also after a new cylinder has been attached to the delivery device and introduced new quantities of O 2 (in air) into the delivery device. Another critical period is the termination of the administration of NO to a patient and the delivery system shut off. At that latter time, unless the cylinder valve controlling the supply of NO containing therapy gas is turned to the off position to isolate the NO supply from the NO delivery system, there is the possibility that any O 2 remaining in the conduits of the regulator during the shut down period may migrate back into the cylinder of NO containing therapeutic gas and contaminate that cylinder of gas. EP-0 654 445 describes a NO delivery system including a conduit for connection between a source of NO and a patient, a value for controlling the flow of NO and a purge value for purging the system. SUMMARY OF THE INVENTION In accordance with the present invention, there is provided a nitric oxide delivery system where a volume of NO is administered to the patient and where certain safety steps are carried out to eliminate NO 2 from the system to prevent the inadvertent administration of a toxic concentration of NO 2 to the patient. Therefore, as an aspect of the present invention, at the start up of the system, as indicated, there may be NO 2 that formed in the various conduits during the time period when the delivery system was idle. At this point, therefore, the system may, upon the initiation of start-up, provide a visual or audible prompt to the user to carry out the purge manually or, in the alternative, there may be an automatic purge at the initiation of that start-up. In either case, the purge rids the system of any NO 2 that may have formed during the time period the system was not in use. As a further aspect of the present invention, the delivery system detects when the delivery of NO to the patient has been discontinued by the user and the system then either senses the discontinuance of the NO administration and provides a visual and/or audible prompt to the user so that the user can manually shut off the cylinder valve or, alternatively, automatically shuts off the cylinder valve to prevent O 2 from migrating back into the cylinder thereby isolating the NO supply from the various conduits and regulator of the NO delivery system. Completion of this step can be confirmed by the system by checking that the flow or pressure in the system goes to zero when a purge is performed after the cylinder valve is turned off. If the valve has not been turned off the pressure or flow during a purge will remain at previous levels and the system can continue the prompt to the user that the cylinder valve needs to be shut off. The present invention is described in the accompanying claims. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic view of a NO delivery system constructed in accordance with the present invention where the user is prompted to perform the purge task; and Figure 2 is a logic diagram for a purge scheme using the NO delivery system shown in Figure 1 DETAILED DESCRIPTION OF THE INVENTION Turning now to Figure 1, there is shown a schematic view of a pulsed dosing nitric oxide (NO) delivery system constructed in accordance with the present invention. A gas cylinder 10 is provided containing the therapeutic amount of nitric oxide. Preferable that NO gas is mixed with a balance or carrier gas such as nitrogen and the concentration may be in the order of 100 ppm. The NO in nitrogen gas is available commercially in cylinders at pressures of approximately 2000 psig. Atop the gas cylinder 10 is a cylinder valve 12 and which controls the supply of NO containing therapy gas to the overall NO delivery system. As will be explained, the cylinder valve 12 may be of the manually operated type or may be controlled by a remote signal, such as by a electrical signal operating a solenoid valve. A pressure regulator 14 is located just downstream of the cylinder valve 12 and reduces the cylinder pressure down to a working pressure for use with the present system and that pressure may be in the order of about 50 psig. The pressure regulator 14 is connected to the cylinder 10 by a connector 13. A pressure gauge 16 is generally provided on the pressure regulator 12 in order to keep track of the pressure within the gas cylinder 10. A conduit 18 carries the NO containing therapy gas from the pressure regulator 14 through to a patient 20 where the NO containing therapy gas is administered to the patient by means such as a patient utilization device 22, an example of which is a nasal cannula (not shown). It is sufficient to note that the patient utilization device 22 has an opening that communicates the NO containing therapy gas to the patient for inhalation thereof. A control valve 30 controls the flow of NO containing therapy gas from the gas cylinder 10 to the patient 20 and is a solenoid controlled valve operated by a signal from a controller 28 which may be a central processing unit (CPU), logic circuit or analog circuit. Again, for safety, the control valve 30 is preferably normally closed and is moved to its open position when a signal energizes the valve by the controller 28. The control valve 30 is operated by the controller 28 in accordance with timed or other means of sending pulses of NO containing therapy gas to the patient and the particular algorithm of control is not a part of the present invention. A user input device 32 allows the user to turn the NO delivery system to the on or the off condition. The user input device 32, at the same time, signals the appropriate condition to the controller 28. Also as a part of the system, there may be an audio alarm 34 and/or a visual display 36 to alert the user to certain conditions of the NO delivery system. A user purge input device 38 allows the user to initiate the purge cycle. The user purge input device 38, at the same time, signals the appropriate condition to the controller 28. Sensor 40 is provided to act as a monitor of certain parameters in the NO delivery system and the sensor 40, as will become apparent, may be a flow sensor, a pressure sensor or the like and which may be connected to the conduit 18 to sense that parameter at a location 42 between the gas cylinder 10 and the pressure regulator 14, at a location 44 between the pressure regulator 14 and the control valve 30, or at a location 46 between the control valve 30 and the patient utilization device 22. As shown, the preferred location is at the location 46 and that sensor communication is shown as a solid line, the other locations 42 and 44 are indicated as dashed lines. Turning now to Figure 2, there is shown a flow chart, taken along with Figure 1, and which describes the overall operation of the NO delivery system. As noted, upon start-up of the system, the gas cylinder 10 containing the NO therapy gas in a predetermined concentration is opened and the NO containing therapy gas enters the pressure regulator 14 and the conduit 18. The user initiates the NO delivery system by the user input device 32 being set to the on position, and which "on" signal is communicated to the controller 28. At this point, since the NO delivery system is being initiated, there is a likelihood that some NO 2 may have formed in the conduit 18 or other parts of the delivery system since there may have been a considerable passage of time from the last use of the NO delivery system to allow the reacting of any remaining NO and O 2 to have occurred or a new therapy gas cylinder 10 could have been connected to the delivery system allowing air to enter the system at the connector 13. According, the system must be initially purged to assure that no NO 2 is present in any of the various components. Upon the turning "on" of the device at 60, the controller 28 activates a purge prompt at 62 to inform the user to purge the system by audio alarm 34 and/or the visual display 36. Activation of the purge at 64 by the user purge input device 38 opens the control valve 30 for a predetermined time at 66. During that time period the controller 28 determines if sufficient pressure, or flow, or the like, was present at 68 from the signal from sensor 40. As noted, the sensor 40 may be detecting various parameters of the gas in conduit 18, preferably flow or pressure. If not, at 70 the controller 28 alerts the user that a purge was not successful by audible alarm 34 and/or the visual display 36. If the sensor 40 detected sufficient pressure, or flow, or the like, at function 68 the controller 28 informs the user that a purge was performed successfully at 72 by the audible alarm 34 and/or the visual display 36. Taking, now, the "shut down" cycle, upon the turning "off" of the device at 80, the controller 28 activates a purge prompt at 82 to inform the user to purge the NO delivery system by the audio alarm 34 and/or the visual display 36. Activation of the purge at 84 by the user purge input device 38 opens the control valve 30 for a predetermined time at 86. During that time period the controller 28 determines if the pressure, or flow, or the like, from the signal from sensor 40, has decayed at 88 indicating that the cylinder valve 12 has been closed. The controller 28 then informs the user that a purge was performed successfully at 90 by the audible alarm 34 and/or the visual display 36. If the sensor 40 detects that the pressure, or flow, or the like, has not decayed and therefore indicating that the cylinder valve 12 has not been closed, then the controller 28 alerts the user that a purge was not successful at 92, by the audible alarm 34 and / or the visual display 36. Accordingly, by a mandatory purge carried out automatically or by prompt to the user, at the initiation of the use of the NO delivery system and a mandatory or user prompted bleed purge at the cessation of the NO delivery system along with a verification that the NO supply has been isolated from the delivery system, the NO 2 is effectively controlled and the possibility of NO 2 being inadvertently introduced to the patient during the NO therapy is greatly minimized. Numerous further variations and combinations of the features discussed above can be utilized without departing from the spirit of the invention as defined by the claims below. Accordingly, the foregoing description of the preferred embodiment should be taken by way of illustration rather than by way of limitation of the invention as claimed.

Claims: A nitric oxide delivery system for delivering a therapeutic amount of nitric oxide in predetermined pulses, said system comprising: a conduit (18) adapted to be connected at one end to a source gas (10) containing nitric oxide (NO) under pressure and at the other end to a patient utilization device (22) for communicating the NO containing therapy gas to a patient (20) through the patient utilization device (22), a user input device (32) operable by a user and having an activated position where said nitric oxide delivery system is operable and an inactive position, a valve (30) in said conduit (18) adapted to open and close to deliver the NO-containing therapy gas to a patient in predetermined pulses, said valve (30) being openable to release gas from the conduit (18) to purge gas from said conduit (18) through the said other end, a controller (28) arranged to provide a signal to said valve to open said valve in response to said user input device (32) being selected to said activated or to said inactivated position and a sensor (40) to detect a parameter of the gas, e.g. gas pressure or gas flow, at a location in said conduit (18) and to provide a signal to said controller (28) indicative of that parameter to verify that said valve (30) has been opened and said conduit is being purged wherein the controller is configured to determine whether the sensor (40) has detected that a sufficient parameter of the gas, e.g. gas pressure or gas flow, has been present to provide a successful purge. A delivery system as defined in Claim 1 wherein said sensor is a pressure sensor or a flow sensor. A delivery system as defined in Claim 1 wherein said sensor (40) is located between the valve (30) and a patient utilization device (22). A delivery system as defined in any one of claims 1 to 3, that is useable with a source valve (12) intermediate said conduit (18) and a supply of source gas (10) containing NO, said source valve (12) having an off position whereby said conduit (18) is isolated from the supply of source gas (10) and having an on position, and wherein, when said user input device (32) is operated by a user to said inactive position, the sensor (40) monitors the said parameter of the gas in said conduit (18) to verify that said source valve is in the off position and that said conduit is being purged. A delivery system as defined in Claim 4, wherein said controller (28) and the sensor (30) determine whether the said parameter has decayed, thereby indicating that source valve (12) is in the off position. A system as defined in any of Claims 1 to 5, wherein said system further comprises a prompt to alert the user of information, said prompt providing information concerning whether or not the purge was successful. A system as claimed in claim 6 when dependent on claim 4, wherein the prompt provides an indication if the source valve (12) has not been closed. A system as defined in Claim 6 or claim 7 wherein said prompt is an audio alarm (34) and/or a visual display (36). A method of purging a nitric oxide delivery system having a conduit (18) to deliver a gas containing nitric oxide from a source of nitric oxide (10) to a patient utilization device (22) and having a power selector device (32) to turn said system to an active and an inactive status, said method comprising; (a) turning the power selector device (32) to the active position or to the inactive position; (b) purging the conduit (18) of gas by passing a gas through the conduit for a predetermined time, wherein said purging gas is not introduced to a patient; (c) sensing a parameter of the gas passing through the conduit (18) to verify that the purging is taking place; and (d) providing a prompt to a user indicating that a purge has been completed. A method as claimed in claim 19, wherein the system includes a source valve (12) intermediate said conduit (18) and the source of NO containing therapy gas (10), said source valve (12) having a closed position and an open position and wherein the method includes, when turning the power selector to the inactive position in step (a), the additional step of closing the supply valve. A method as claimed in claim 10, wherein, in step (c), the sensing of a parameter of the gas passing through the conduit (18) when turning the power selector (32) to the inactive position verifies that the source valve (12) is closed. A method as claimed in claim 10 or 11, wherein the system provides a visible or audible prompt (34,36) to the user to shut off the source valve (12) when the power selector device (32) is turned to the inactive position. A method as claimed in claim 10 or 11, wherein the system shuts off the source valve (12) automatically when the power selector device (32) is turned to the inactive position. A method as claimed in any one of claims 9 to 13, wherein the system carries out the purge automatically when the power selector device (32) is turned to the active position. A method as claimed in any one of claim 9 to 13, wherein the system provides a visible or audible prompt (34,36) to the user to carry out the purge manually when the power selector device (32) is turned to the active position. A method as claimed in any one of claims 10 to 13, wherein said parameter sensing step (d) comprises sensing the flow of the gas in the conduit (18) or the pressure of the gas in the conduit (18).

Inventors: BATHE DUNCAN P L, MONTGOMERY FREDERICK J, BATHE, DUNCAN P.L., MONTGOMERY, FREDERICK J.
Applicants: INO THERAPEUTICS LLC
Application year: 1998
Main classification: A61M16
IPC codes: A61M16